BMY Loses 16.3% YTD: Should You Buy, Sell or Hold the Stock?

Bristol Myers Squibb (BMY) shares have significantly underperformed year-to-date, down 16.3%, primarily due to persistent generic competition impacting key legacy drugs like Revlimid and Eliquis, alongside recent pipeline setbacks for promising assets such as Camzyos and Cobenfy. While BMY is actively diversifying its portfolio with newer drugs like Opdualag, Reblozyl, and Breyanzi, and pursuing strategic collaborations, these efforts have not yet fully offset the headwinds, which also include substantial acquisition-related debt and downward revisions to future earnings estimates, leading to investor caution despite an attractive dividend yield.

Analysis

Bristol Myers Squibb (BMY) is facing significant investor skepticism, reflected in its 16.3% year-to-date share price decline, which starkly underperforms its industry. The primary headwinds are persistent generic competition for legacy blockbusters like Revlimid and a 4% Q1 sales dip in its top drug, Eliquis, attributed to the U.S. Medicare Part D redesign. This pressure is compounded by recent pipeline setbacks, including the failure of a late-stage study for Camzyos in non-obstructive hypertrophic cardiomyopathy and a disappointing phase III study for Cobenfy as an adjunctive schizophrenia treatment. Despite these challenges, the company is executing a strategic pivot toward a newer product portfolio, with drugs like Reblozyl, Breyanzi, and Opdualag showing strong uptake and stabilizing the revenue base. Key regulatory wins, such as the approval of a subcutaneous formulation for Opdivo and the FDA's green light for Cobenfy as a novel monotherapy for schizophrenia, offer future growth potential. However, the balance sheet remains a concern with a substantial debt load of $46.1 billion against $12.1 billion in cash. The stock's valuation appears compressed, trading at a 7.24x forward P/E ratio, well below its historical mean and the industry average, signaling that the market is currently weighing the risks of generic erosion and pipeline execution more heavily than the potential of its new assets.

Key Decisions for Investors

• Given the significant headwinds from generic competition and recent pipeline failures, prospective investors should consider a cautious stance, waiting for clear evidence that the new product portfolio's growth can materially offset the decline in legacy drug revenue.
• For current shareholders, maintaining the position could be justified by the attractive 5.35% dividend yield, which offers a substantial income stream while the company navigates its transition.
• Investors should closely monitor the commercial performance of key growth drivers like Reblozyl, Breyanzi, and the newly launched Cobenfy, as their sales trajectory is the primary catalyst for a potential stock re-rating.
• The high debt level of $46.1 billion is a critical risk factor to watch, as it could limit strategic flexibility and amplify downside risk if revenue from the new drug portfolio underperforms expectations.